SANGAMO THERAPEUTICS ($SGMO) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.14 per share, missing estimates of -$0.13 by $0.01. The company also reported revenue of $6,440,000, missing estimates of $7,565,003 by $-1,125,003.
You can see Quiver Quantitative's $SGMO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SANGAMO THERAPEUTICS Hedge Fund Activity
We have seen 57 institutional investors add shares of SANGAMO THERAPEUTICS stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP removed 10,210,863 shares (-52.5%) from their portfolio in Q4 2024, for an estimated $10,415,080
- STATE STREET CORP added 4,354,414 shares (+655.2%) to their portfolio in Q4 2024, for an estimated $4,441,502
- POINT72 ASSET MANAGEMENT, L.P. added 2,270,550 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,315,961
- MARSHALL WACE, LLP removed 2,016,626 shares (-85.7%) from their portfolio in Q4 2024, for an estimated $2,056,958
- IKARIAN CAPITAL, LLC added 1,860,179 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,897,382
- RENAISSANCE TECHNOLOGIES LLC removed 1,767,900 shares (-36.4%) from their portfolio in Q4 2024, for an estimated $1,803,258
- SCHONFELD STRATEGIC ADVISORS LLC added 1,709,615 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,743,807
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SANGAMO THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SGMO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 12/31/2024
- Jefferies issued a "Buy" rating on 12/31/2024
- Cowen & Co. issued a "Buy" rating on 12/31/2024
- Barclays issued a "Overweight" rating on 12/31/2024
To track analyst ratings and price targets for SANGAMO THERAPEUTICS, check out Quiver Quantitative's $SGMO forecast page.
SANGAMO THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SGMO recently. We have seen 2 analysts offer price targets for $SGMO in the last 6 months, with a median target of $2.5.
Here are some recent targets:
- Maury Raycroft from Jefferies set a target price of $3.0 on 12/31/2024
- Yanan Zhu from Wells Fargo set a target price of $2.0 on 12/31/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
